StockNews.com Initiates Coverage on Arcadia Biosciences (NASDAQ:RKDA)

Posted by Casey Walker on Feb 13th, 2025

StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the basic materials company’s stock.

Arcadia Biosciences Trading Up 1.1 %

Shares of RKDA stock opened at $4.81 on Tuesday. Arcadia Biosciences has a 1 year low of $1.85 and a 1 year high of $10.31. The firm’s 50 day moving average is $5.49 and its 200-day moving average is $3.92. The firm has a market capitalization of $6.54 million, a price-to-earnings ratio of -1.12 and a beta of 0.88.

Hedge Funds Weigh In On Arcadia Biosciences

An institutional investor recently bought a new position in Arcadia Biosciences stock. Geode Capital Management LLC bought a new position in Arcadia Biosciences, Inc. (NASDAQ:RKDA – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 12,297 shares of the basic materials company’s stock, valued at approximately $73,000. Geode Capital Management LLC owned 0.90% of Arcadia Biosciences as of its most recent filing with the Securities & Exchange Commission. 17.73% of the stock is currently owned by hedge funds and other institutional investors.

Arcadia Biosciences Company Profile

(Get Free Report)

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.